TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06693999

Intervention type: DEVICE
Group type: OTHER
Intervention: Google-Pixel Watch 3
Description: The participant will wear Google-Pixel Watch 3 for at least 10 hours during the 3-month intervention and will receive goal reminders and motivational and coping messages through those watches. At baseline and after 3-months intervention, demographics (standard questionnaire pertaining to subjects' age, sex, race, education and income), technology literacy (eHealth Literacy Scale pertaining to subjects' ability to perform a number of tasks such as turning on the device, using internet and communication), and wearables affinity (pertains to how the subject currently uses wearable in their daily living tasks) will be measured.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Exercise prompts
Description: The participants will receive goal reminders.
Study: NCT06688136

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ropivacaine
Description: Ropivacaine 200 mg diluted to 50 mL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ropivacaine
Description: Ropivacaine 200 mg diluted to 50 mL
Study: NCT06690398

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumateperone high dose
Description: Lumateperone administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumateperone low dose
Description: Lumateperone administered orally once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo administered orally once daily
Study: NCT06696092

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hemostatic Agent
Description: WoundClot Surgical may be used in a single target bleeding site of each subject.
Study: NCT06697392

Intervention type: OTHER
Intervention: ultrasound examination
Description: The investigators intend to perform ultrasound examinations for the participants with CTS.
Study: NCT06697600

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: UR-GOAL
Description: Patients will view an AML video, complete the best/worst scaling, will be provided with a summary report, and will be asked to review and discuss at upcoming clinical visits. Caregivers, if available, will view an AML video, will be provided with a summary report, and will be asked to review. Oncologists will be provided with a summary report and will be asked to review and discuss at upcoming clinical visits.
Study: NCT06701825

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Tacrolimus at the dosage reccomended by the Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing based on the subjects pharmacogenetic phenotype.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Subject allocated to this arm will receive tacrolimus according to clinical practice and the drug's product labelling. These subject will not receive a personalised dose based on their pharmacogenetic phenotype.
Study: NCT05592613

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Next-generation Reader and ID-Cap System
Description: The digital pill system (DPS) is comprised of an ingestible radiofrequency emitter, integrated into a standard gelatin capsule, which then over-encapsulates the study medication (PrEP or ART). On ingestion, the radiofrequency emitter is activated by chloride ions in the stomach, projecting a signal approximately three feet off the body. This radio signal is acquired by a wearable device (Reader) which stores and forwards data to a smartphone, enabling on-demand access to adherence data. The next-generation Reader is a wrist-borne device.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Next-generation Reader and ID-Cap System
Description: The digital pill system (DPS) is comprised of an ingestible radiofrequency emitter, integrated into a standard gelatin capsule, which then over-encapsulates the study medication (PrEP or ART). On ingestion, the radiofrequency emitter is activated by chloride ions in the stomach, projecting a signal approximately three feet off the body. This radio signal is acquired by a wearable device (Reader) which stores and forwards data to a smartphone, enabling on-demand access to adherence data. The next-generation Reader is a wrist-borne device.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Truvada for pre-exposure prophylaxis (PrEP)
Description: Participants will ingest one Truvada digital pill as PrEP per day, for 30 days total.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biktarvy for antiretroviral therapy (ART)
Description: Participants will ingest one Biktarvy digital pill as ART per day, for 30 days total.
Study: NCT06711679

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low-dose ropivacaine
Description: 0.5 ml/Kg ropivacaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low-dose ropivacaine
Description: 0.5 ml/Kg ropivacaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low-dose ropivacaine
Description: 0.5 ml/Kg ropivacaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low-dose ropivacaine
Description: 0.5 ml/Kg ropivacaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medium-dose of ropivacaine
Description: 1ml/Kg ropivacaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medium-dose of ropivacaine
Description: 1ml/Kg ropivacaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medium-dose of ropivacaine
Description: 1ml/Kg ropivacaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medium-dose of ropivacaine
Description: 1ml/Kg ropivacaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High-dose ropivacaine
Description: 1.5 ml/Kg ropivacaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High-dose ropivacaine
Description: 1.5 ml/Kg ropivacaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High-dose ropivacaine
Description: 1.5 ml/Kg ropivacaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High-dose ropivacaine
Description: 1.5 ml/Kg ropivacaine
Study: NCT06711523

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-G-CSF injection (Kexing Biopharmaceutical Co., Ltd.)
Description: This trial was conducted using the IWRS system where subjects were randomly assigned to the test group (PEG-G-CSF injection (Kexing Biopharmaceutical Co., Ltd.)) and control group (Neulasta®，Amgen Europe B.V.) in a 1:1 ratio.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PEG-G-CSF injection (Neulasta®，Amgen Europe B.V.)
Description: This trial was conducted using the IWRS system where subjects were randomly assigned to the test group (PEG-G-CSF injection (Kexing Biopharmaceutical Co., Ltd.)) and control group (Neulasta®，Amgen Europe B.V.) in a 1:1 ratio.
Study: NCT06711380

Intervention type: OTHER
Group type: OTHER
Intervention: Peer Ambassador
Description: Patient mentor (patient with history of gynecologic cancer who has experience with clinical trials) one on one discussion with patient mentee (patient receiving standard of care treatment for gynecologic cancers).
Study: NCT06708325

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Training Program
Description: The 12-week resistance training program consisted of three supervised sessions per week, each lasting approximately 55-60 minutes. Sessions were structured as follows: 5-7 minute dynamic warm-up, 35-40 minutes of resistance training, and 4-5 minutes of stretching for active recovery.Participants were paired based on similar strength fitness levels and progressed according to the principle of periodized progressive overload. Training was delivered using a circuit protocol with 2-3 sets per exercise. The initial 4-week phase included 2 sets per exercise, with 8-20 repetitions and 1-2 minutes rest between sets. .The program incorporated functional exercises targeting the lower extremities, core, and upper extremities, utilizing equipment such as resistance bands, medicine balls, jump ropes, dumbbells, bars, and stability balls. Participants performed exercises in a circuit sequence, with the intensity, number of sets, and repetitions
Study: NCT05765617

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcitriol
Description: The treatment group received calcitriol 2x400 iu per day for five days. Calcitriol uses Oscal, obtained from Kalbe Pharma

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo give 2x1 per day for five day
Study: NCT06711653

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Vestibular evoke myogenic potential
Description: routine Vestibular test
Study: NCT06713018

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Three cannulated compression screws by navigation system
Description: Patients with femoral neck fractures treated with three cannulated compression screws assisted by a navigation system

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Traditional three cannulated compression screws
Description: Patients with femoral neck fractures treated with traditional three cannulated compression screws
Study: NCT06705491

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TIPPI-R
Description: The TIPPI-R intervention protocol consists of a one session, during which time the interventionist offers psychoeducation related to the following content areas: procedural pain related to oncology treatment, factors that may affect the perception of pain, evidenced-based tools for assessing and monitoring pain, cognitive and behavioral pain management interventions, and resources to facilitate family to advocacy for pain management in a medical setting. During this session, the interventionist discusses opportunities for families to utilize skills throughout treatment, and addresses family questions as needed. A follow-up session 4 weeks after the initial intervention session will assess family knowledge and skills and offer a referral for a mental health provider, if further pain management support is needed. TIPPI-R is designed to be delivered by a psychologist, psychology trainee, or social worker working in the oncology context.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TIPPI-R
Description: The TIPPI-R intervention protocol consists of a one session, during which time the interventionist offers psychoeducation related to the following content areas: procedural pain related to oncology treatment, factors that may affect the perception of pain, evidenced-based tools for assessing and monitoring pain, cognitive and behavioral pain management interventions, and resources to facilitate family to advocacy for pain management in a medical setting. During this session, the interventionist discusses opportunities for families to utilize skills throughout treatment, and addresses family questions as needed. A follow-up session 4 weeks after the initial intervention session will assess family knowledge and skills and offer a referral for a mental health provider, if further pain management support is needed. TIPPI-R is designed to be delivered by a psychologist, psychology trainee, or social worker working in the oncology context.
Study: NCT06712888

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TORIPALIMAB INJECTION (JS001 ) combine with GP chemotherapy
Description: Drug: Toripalimab 240mg will be given every 3 weeks for 3 cycles, started on day 1 of induction chemotherapy.~Other Names:~JS001 PD-1 antibody~Drug: Gemcitabine 1000mg/m2, d1 \& 8 of every cycle, every 3 weeks for 3 cycles before radiation.~Drug: Cisplatin Induction cisplatin 80mg/m2, every 3 weeks for 3 cycles before radiation; Concurrent cisplatin 100mg/m2, every 3 weeks for 3 cycles during radiation~Other Names:~DDP~Radiation: intensity-modulated radiotherapy Definitive intensity-modulated radiotherapy (IMRT) of 70 Gy will be given in 33 fractions.~Other Names:~IMRT

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GP plus placebo induction therapy
Description: Drug: Placebo 240mg will be given every 3 weeks for 3 cycles, started on day 1 of induction chemotherapy.~Drug: Gemcitabine 1000mg/m2, d1 \& 8 of every cycle, every 3 weeks for 3 cycles before radiation.~Drug: Cisplatin Induction cisplatin 80mg/m2, every 3 weeks for 3 cycles before radiation; Concurrent cisplatin 100mg/m2, every 3 weeks for 3 cycles during radiation~Other Names:~DDP Radiation: intensity-modulated radiotherapy Definitive intensity-modulated radiotherapy (IMRT) of 70 Gy will be given in 33 fractions.~Other Names:~IMRT
Study: NCT06711289

Intervention type: DIAGNOSTIC_TEST
Intervention: Carotid ultrasound measurement
Description: Pulsed-wave Doppler acquisition of the carotid artery. One acquisition will be made with the slow-speed setting (33 mm/s) and one with the medium-speed setting (66 mm/s).

Intervention type: DIAGNOSTIC_TEST
Intervention: Carotid ultrasound measurement
Description: Pulsed-wave Doppler acquisition of the carotid artery. One acquisition will be made with the slow-speed setting (33 mm/s) and one with the medium-speed setting (66 mm/s).

Intervention type: DIAGNOSTIC_TEST
Intervention: Vital sign measurement
Description: Measurement of noninvasive blood pressure, at different time points before and after the induction of spinal anesthesia.

Intervention type: DIAGNOSTIC_TEST
Intervention: Vital sign measurement
Description: Measurement of noninvasive blood pressure, at different time points before and after the induction of spinal anesthesia.

Intervention type: DRUG
Intervention: Spinal anesthesia
Description: Following the standard of care, the patients received spinal anesthesia. The type and dosage of the local anesthetic were at the discretion of the treating anesthesiologist.

Intervention type: DRUG
Intervention: Spinal anesthesia
Description: Following the standard of care, the patients received spinal anesthesia. The type and dosage of the local anesthetic were at the discretion of the treating anesthesiologist.
Study: NCT05226741

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Head protection device
Description: The participants are fitted with a form of head protection over the craniectomy and provide feedback on design, use, and comfort
Study: NCT05376943

Intervention type: DRUG
Intervention: Direct Acting Antivirals
Description: Our observational study will assess the exposure to direct acting antivirals - the specific drugs, dose, duration of the therapy and the effect of the treatment.
Study: NCT06024031

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetyl-L-cysteine
Description: N-acetyl-L-cysteine (Yiweishi) capsules (Guangdong Renrenkang Pharmaceutical Industry) will be given orally 400mg three times a day from day 1 to day 28 after chemotherapy. In case of drug allergy such as nausea, vomiting, rash and bronchospasm, and disease relapse, to discontinue the drug immediately.
Study: NCT06349096

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alma Harmony
Description: The ClearLift is a class IIb medical device, High Power Q-switched (QS) 1064nm Nd:YAG laser module in the Harmony system. It has a targeted laser module for the non-invasive removal of various colored tattoos, as well as deep and superficial benign pigmented lesions, wrinkles, fine lines, and skin tightening.
Study: NCT06015672

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Magnetic Stimulation (TMS)
Description: Participants will experience three accelerated transcranial magnetic stimulation (TMS) sessions, with 12 week (three-months) gap between each session.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Magnetic Stimulation (TMS)
Description: Participants will experience three accelerated transcranial magnetic stimulation (TMS) sessions, with 12 week (three-months) gap between each session.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Magnetic Stimulation (TMS)
Description: Participants will experience three accelerated transcranial magnetic stimulation (TMS) sessions, with 12 week (three-months) gap between each session.
Study: NCT05856058

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR0302
Description: SHR0302 oral solution 1 time, SHR0302 tablets 1 time

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR0302
Description: SHR0302 oral solution 1 time, SHR0302 tablets 1 time
Study: NCT05316688

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Near Infrared Imaging
Description: Undergo NIR imaging

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tozuleristide
Description: Given IV
Study: NCT06039410

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ISO-101
Description: ISO-101 is an experimental wearable class 1 medical device which when used is able to raise the blood pressure upon standing via controlled isometric muscular contractions
Study: NCT05521568

Intervention type: DIAGNOSTIC_TEST
Intervention: Index test: Abbott ID NOW STREP A 2
Description: The test under evaluation ('index test') is the rapid molecular test for Group A streptococcus Abbott ID NOW STREP A 2 (performed on saliva samples instead of throat swabs). This test was chosen because of its ease of use and several previous evaluations showing high diagnostic accuracy on throat swabs. The test gives a result after 2 to 6 minutes and will be performed by primary care practitioners participating in the study, in their office, using salivary swabs instead of throat swabs. Investigators will receive one session of specific training prior to the study. Saliva samples will be collected using the cotton swab that comes within the test packages. Index test results will not be used for patient management. Clinicians performing the rapid saliva test will not be blinded to clinical information.

Intervention type: DIAGNOSTIC_TEST
Intervention: Reference standard test: Composite of culture and PCR-based tests based on a throat swab
Description: Throat samples will be obtained by use of a double-swab collection-transportation system :~* Swab #1 will be used to perform the rapid antigen detection test (see below)~* Swab #2 will be held at ambient temperature and sent within 72 hours to Robert Debre Hospital microbiology laboratory. Throat swabs will be used to perform throat cultures using standard techniques (PMID: 22768060). Throat swabs will also be used to perform a PCR specific for Group A streptococcus (PMID: 23465407). Samples with a positive culture and/or a positive PCR test result will be classified as reference-standard-positives. Samples with a negative culture and a negative PCR will be classified as reference-standard-negatives. Investigators will be blinded to clinical data, including the result of the rapid antigen detection test and the rapid saliva test.

Intervention type: DIAGNOSTIC_TEST
Intervention: Comparator test: Rapid antigen detection test (usual care)
Description: As per usual care, all children will undergo a rapid antigen detection test (StreptAtest, Biosynex), using Swab#1 (see above). This rapid antigen detection test is the one used in France and is the only commercial kit that is officially recommended by the National Health Insurance system. It detects Lancefield's Group A antigen, which is specific to Group A Streptococcus. The test will be performed by investigators, during consultation time. Clinicians performing the rapid antigen detection test will not be blinded to clinical information.
Study: NCT05850312

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gamified Digital Intervention - Feasibility Analysis on MoM
Description: In first round we aim to clinically analyze the game Militant of the Maze (MoM) as a vehicle for Exposure Theory, including, play, observation, and feedback from five clinicians.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gamified Digital Intervention
Description: In the first phase of round 2 of the study, 5 clinicians will play the game to evaluate the revised game MoMG. In the next phase, 5 carefully-selected non-clinician participants will play the game. under real-time observation of clinicians, to ensure that subjects experience no harm, and that the gameplay is interesting and enjoyable.
Study: NCT05354505

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Placement of the GOLDBAL2 balloon
Description: The Fetal Endoscopic Tracheal Occlusion (FETO) procedure using the Goldballoon Detachable Balloon (GOLDBAL2) along with the Delivery Microcatheter (BALTACCI-BDPE100) will be used to treat fetuses diagnosed with severe Congenital Diaphragmatic Hernia (CDH)
Study: NCT06713291

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sliding compression locking plate
Description: The patients with femoral neck fracture were treated with three cannulated compression screws or sliding compression locking plate.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Three cannulated compression screws
Description: The patients with femoral neck fracture were treated with three cannulated compression screws.
Study: NCT06714292

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic Clipping
Description: localization of colon lesion with fluorescent clip
Study: NCT05526157

Intervention type: DRUG
Intervention: Glucagon-like peptide-1 receptor agonists (GLP 1 RA)
Description: Retrospective analysis using secondary data collection from various sources

Intervention type: DRUG
Intervention: Glucagon-like peptide-1 receptor agonists (GLP 1 RA)
Description: Retrospective analysis using secondary data collection from various sources

Intervention type: DRUG
Intervention: Steroidal mineral corticoid receptor antagonists (sMRA)
Description: Retrospective analysis using secondary data collection from various sources
Study: NCT06714292

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ICG injection
Description: localization of colon lesion with ICG(indocyanine green) through endoscopic tattooing
Study: NCT06713980

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham acupuncture
Description: In the sham acupuncture group, sham acupuncture was applied at 14 specific non-acupuncture points on the back.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: acupuncture:the choice of acupoints was based on the theory of traditional Chinese medicine (TCM). All needles were manually manipulated to achieve the deqi sensation
Study: NCT06713044

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Murottal Therapy Intervention Name: Murottal (Islamic verse recitation)
Description: To evaluate whether murottal recitations can reduce postoperative pain intensity and lower interleukin 6 levels, which are indicative of inflammation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Classical Music Therapy Intervention Name: Classical Music Listening
Description: To evaluate the impact of classical music on reducing postoperative pain intensity and interleukin 6 levels in the body, thereby managing inflammation.